EVALUATION OF VARIOUS ANALOGS OF TILORONE HYDROCHLORIDE AGAINST VENEZUELAN EQUINE ENCEPHALITIS-VIRUS IN MICE

EVALUATION OF VARIOUS ANALOGS OF TILORONE HYDROCHLORIDE AGAINST VENEZUELAN EQUINE ENCEPHALITIS-VIRUS IN MICE
复制标题

DOI:
10.1128/aac.11.1.92
复制
发表时间:
1977-01-01
影响因子:
4.9
通讯作者:
STEPHEN, EL
STEPHEN, EL
中科院分区:
医学2区
文献类型:
--
作者:
KUEHNE, RW;PANNIER, WL;STEPHEN, EL

文献摘要

被引文献

相似文献

用口服和腹腔注射的方法评价了盐酸替罗龙及其类似物(11,002,11,567和11,877)的抗病毒活性。给委内瑞拉马脑炎(VEE)病毒感染的小鼠注射。口服250和500 mg/kg的替诺龙和类似物11877可显著提高小鼠的存活率(P<0.01)。腹腔注射剂量为31.25~500 mg/kg时,替诺龙和11877均不能增加存活率。路线。口服类似物11,002对100只小鼠脑内VEE病毒的半数致死量(MICLD50)为250~1000 mg/kg,ip剂量为31.25~250 mg/kg。对10 MICLD50有效。口服剂量为每公斤11567毫克至1000毫克的类似物对100 MICLD50的病毒有活性。由IP提供。每公斤11567毫克的250毫克剂量可保护小鼠抵抗1000 MICLD50,而125毫克/公斤的剂量则可保护小鼠抵抗100 MICLD50。皮下接种VEE病毒24小时后,口服类似物11,567对VEE感染小鼠的存活率无显著影响。所有这些研究的幸存者都有可能在第一次接种病毒后21天再次挑战。
The antiviral activity of tilorone hydrochloride and three of its analogues (11,002, 11,567, and 11,877) was assessed by oral and intraperitoneal (i.p.) administration to Venezuelan equine encephalitis (VEE) virus-infected mice. Significant increases in the percentage of survival (P< 0.01) were apparent after oral administration of tilorone and analogue 11,877 at dosages of 250 and 500 mg/kg. Neither tilorone nor 11,877 increased percentage of survival when dosages of 31.25 to 500 mg/kg were given by the i.p. route. Orally administered analogue 11,002 was effective against 100 mouse intracranial median lethal doses (MICLD50) of VEE virus at doses at 250 to 1,000 mg/kg; doses of 31.25 to 250 mg/kg given i.p. were effective against 10 MICLD50. Oral dosages of 250 to 1,000 mg of analogue 11,567 per kg were active against 100 MICLD50of virus. By the i.p. route, 250 mg of 11,567 per kg protected mice against 1,000 MICLD50, and a dose of 125 mg/kg protected against 100 MICLD50. Oral treatment of VEE infection with analogue 11,567 24 h after subcutaneous inoculation of VEE virus resulted in no significant increase in the percentage of survivors. All survivors of these studies were susceptible to rechallenge 21 days after the first inoculation of virus.